clinical trial · NCT07033481
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
EIP Pharma Inc·phase2·recruiting·n = 20
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)NeflamapimodPlacebo
brief summary
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
started
Oct 2, 2025
primary completion
Sep 1, 2026
completion
Oct 1, 2026
last updated
Apr 22, 2026
official title
A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol